Lukas, J.; Cimmaruta, C.; Liguori, L.; Pantoom, S.; Iwanov, K.; Petters, J.; Hund, C.; Bunschkowski, M.; Hermann, A.; Cubellis, M.V.;
et al. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease. Int. J. Mol. Sci. 2020, 21, 956.
https://doi.org/10.3390/ijms21030956
AMA Style
Lukas J, Cimmaruta C, Liguori L, Pantoom S, Iwanov K, Petters J, Hund C, Bunschkowski M, Hermann A, Cubellis MV,
et al. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease. International Journal of Molecular Sciences. 2020; 21(3):956.
https://doi.org/10.3390/ijms21030956
Chicago/Turabian Style
Lukas, Jan, Chiara Cimmaruta, Ludovica Liguori, Supansa Pantoom, Katharina Iwanov, Janine Petters, Christina Hund, Maik Bunschkowski, Andreas Hermann, Maria Vittoria Cubellis,
and et al. 2020. "Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease" International Journal of Molecular Sciences 21, no. 3: 956.
https://doi.org/10.3390/ijms21030956
APA Style
Lukas, J., Cimmaruta, C., Liguori, L., Pantoom, S., Iwanov, K., Petters, J., Hund, C., Bunschkowski, M., Hermann, A., Cubellis, M. V., & Rolfs, A.
(2020). Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease. International Journal of Molecular Sciences, 21(3), 956.
https://doi.org/10.3390/ijms21030956